GlassScriptPhysician profile
Milind V Tilak
NPI 1316960735
$735.70
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.44 · 2020: $166 · 2021: $333 · 2022: $48.22 · 2023: $16.64 · 2024: $97.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $114.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.04 | 2021 | |
| Indivior INC. | $134.22 | 2020-2021 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Orexo US, INC. | $81.04 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $37.74 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Avanir Pharmaceuticals, INC. | $29.72 | 2019 | |
| Pacira Therapeutics, INC. | $22.52 | 2020 | |
| Ucb, INC. | $22.23 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.67 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.64 | 2023 | Menopur |
| Supernus Pharmaceuticals, INC. | $15.50 | 2021 | |
| Kaleo, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milind Tilak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.